Reactive oxygen species-responsive clicked assembly of gold nanoparticles to enhance photothermal therapy

Bui, H.D.; Park, Yeonju; Jung, Young Mee; Chew, Sing Yian; Yoo, Hyuk Sang

doi:10.1039/d3tb00500c

Cited by 11 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 Due to the increased intracellular ROS levels in cancer cells, an alternative option is to employ the ROS-responsive sustained release of gold nanoparticles for photothermal therapy in the NIR-I window. 87 Li and co-workers showcased a comprehensive phototheranostic platform, employing near-infrared II (NIR-II) dual-plasmonic Au@Cu 2− x Se core–shell nanocrystals (dpGCS NCs). This innovative platform integrated photoacoustic (PA) and photothermal (PT) imaging, facilitating chemodynamic therapy (CDT), photocatalytic therapy (PCT), and photothermal therapy (PTT).…”

Section: Nir-responsive Nanomaterialsmentioning

confidence: 99%

Review of NIR-responsive ‘‘Smart’’ carriers for photothermal chemotherapy

Karmakar,

Silswal,

Koner

2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Nir-responsive Nanomaterialsmentioning

confidence: 99%

Review of NIR-responsive ‘‘Smart’’ carriers for photothermal chemotherapy

Karmakar,

Silswal,

Koner

2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Additionally, GNP can serve as contrast agents for various imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), and photoacoustic imaging, providing real-time visualization of tumors and facilitating accurate diagnosis and monitoring of treatment response [40][41][42][43]. Furthermore, GNP can be utilized in photothermal therapy, where they convert absorbed light energy into heat, selectively ablating cancer cells while sparing healthy tissue [43,44]. With ongoing research and advancements, gold nanoparticles hold great potential as therapeutics and imaging agents in a wide range of medical applications, offering opportunities for personalized and precise treatments in the future [45,46].…”

Section: Introductionmentioning

confidence: 99%

Gold Nanoparticles Downregulate IL-6 Expression/Production by Upregulating microRNA-26a-5p and Deactivating the RelA and NF-κBp50 Transcription Pathways in Activated Breast Cancer Cells

Farhana,

Alsrhani,

Alghsham

et al. 2024

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are involved in the modulation of pathogenic genes by binding to their mRNA sequences’ 3′ untranslated regions (3′UTR). Interleukin-6 (IL-6) is known to promote cancer progression and treatment resistance. In this study, we aimed to explore the therapeutic effects of gold nanoparticles (GNP) against IL-6 overexpression and the modulation of miRNA-26a-5p in breast cancer (BC) cells. GNP were synthesized using the trisodium citrate method and characterized through UV-Vis spectroscopy, dynamic light scattering (DLS), and transmission electron microscopy (TEM). To predict the binding of miR-26a-5p in the IL-6 mRNA’s 3′UTR, we utilized bioinformatics algorithms. Luciferase reporter clone assays and anti-miRNA-26a-5p transfection were employed to validate the binding of miR26a-5p in the IL-6 mRNA’s 3′UTR. The activity of RelA and NF-κBp50 was assessed and confirmed using Bay 11-7082. The synthesized GNP were spherical with a mean size of 28.3 nm, exhibiting high stability, and were suitable for BC cell treatment. We found that miR-26a-5p directly regulated IL-6 overexpression in MCF-7 cells activated with PMA. Treatment of MCF-7 cells with GNP resulted in the inhibition of IL-6 overexpression and secretion through the increase of miR26a-5p. Furthermore, GNP deactivated NF-κBp65/NF-κBp50 transcription activity. The newly engineered GNP demonstrated safety and showed promise as a therapeutic approach for reducing IL-6 overexpression. The GNP suppressed IL-6 overexpression and secretion by deactivating NF-κBp65/NF-κBp50 transcription activity and upregulating miR-26a-5p expression in activated BC cells. These findings suggest that GNP have potential as a therapeutic intervention for BC by targeting IL-6 expression and associated pathways.

show abstract

“…Nano-scale drug delivery systems have emerged as promising platforms with the potential to improve the stability, solubility, and bioavailability of therapeutic agents while also enabling controlled and sustained release and reducing off-target toxicity. 21–25 In recent years, researchers have developed diverse nanocarriers for efficient delivery of Lu, including micelles, nanoparticles, nanoemulsions, liposomes, exosomes, phospholipid complexes, gels, nanocrystals, and electrospun nanofibers (Scheme 1). These nanoformulations have exhibited impressive advancements in enhancing the solubility and stability of Lu, 26 and facilitating a sustained and controlled release of the compound.…”

Section: Introductionmentioning

confidence: 99%